U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT06961968) titled 'Open-Label Evaluation of Relapse Prevention in Patients With Schizophrenia' on April 29.
Brief Summary: The purpose of this research is to evaluate the relative exposure of iloperidone long-acting injection (LAI) compared to oral iloperidone in patients with schizophrenia.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: iloperidone
iloperidone LAI
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Vanda Pharmaceuticals
Disclaimer: Curated by HT Syndication....